ACE and diabetes mellitus: This trial investigated the effects of the ACE inhibitor ramipril 15 mg/day (n = 2,623) vs placebo (n = 2,646) on the development of diabetes or death (primary outcome) and on the regression to normoglycemia (secondary outcome) in adults aged 30 years or more with IFG and/or IGT, and no previous CV disease.